BioTuesdays

HCW starts Pliant Therapeutics at buy; PT $45

Pliant Therapeutics

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2.

Pliant is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor-beta. The multifunctional cytokine is a central mediator in tissue fibrosis, which is characterized by excessive accumulation of collagen, destroying its normal architecture, ultimately leading to organ dysfunction and failure. 

Pliant’s lead compound, PLN-74809 is enrolling patients in two Phase 2a trials of rare diseases: idiopathic pulmonary fibrosis and primary sclerosing cholangitis, both of which have orphan drug designation from the FDA.

While prior data establishing potent inhibition of gene expression and human proof-of-biological mechanism de-risks clinical development, leveraging advanced diagnostic techniques, including live patient tissue assays, PET and collagen imaging, allows for a “rapid, efficient and rational development path,” writes analyst Ed Arce. 

Beyond PLN-74809, Mr. Arce said a strategic partnership with Novartis on PLN-1474, a selective integrin inhibitor in NASH, provides “meaningful validation for Pliant’s R&D platform,” while preclinical programs in oncology and muscular dystrophies offer optionality. 

“Overall, we anticipate positive top-line results from the INTEGRIS-IPF study in the second quarter of 2022, and expect the first efficacy data in idiopathic pulmonary fibrosis patients to represent a major catalyst for the shares,” he said. 

“Despite positive data to date and risk-reduced profile (multiple monoclonal antibody integrin inhibitors approved), Pliant is currently trading near 52-week lows due to, in our view, macro events leading to a transient sector rotation out of small-cap biotech that in most cases we believe to be overdone. Thus, we view current levels as an excellent entry point,” Mr. Acre said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.